Beta
Retatrutide
medicationTriple agonist GLP-1/GIP/glucagon receptor agonist. Experimental weight loss and metabolic optimization drug. Used off-label in microdoses for longevity.
Reported Benefits
Retatrutide Once Weekly for Obesity: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Jastreboff et al.
In participants with BMI ≥30 or 27-30 with weight-related conditions, retatrutide up to 8mg weekly led to mean weight reductions of up to 17.5% at 24 weeks and 24.2% at 48 weeks, with improvements in cardiometabolic markers.
Phase 2 Trial of Retatrutide in Obesity, Type 2 Diabetes, and NASH
Jastreboff et al.
Retatrutide provided substantial weight reductions at 48 weeks with a tolerability profile similar to other incretin therapies; gastrointestinal side effects were most common during dose escalation.
TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Knee Osteoarthritis
Eli Lilly and Company
Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.
Phase 2 Trial of Retatrutide in Obesity, Type 2 Diabetes, and NASH
Jastreboff et al.
Retatrutide provided substantial weight reductions at 48 weeks with a tolerability profile similar to other incretin therapies; gastrointestinal side effects were most common during dose escalation.
Retatrutide Once Weekly for Obesity: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Jastreboff et al.
In participants with BMI ≥30 or 27-30 with weight-related conditions, retatrutide up to 8mg weekly led to mean weight reductions of up to 17.5% at 24 weeks and 24.2% at 48 weeks, with improvements in cardiometabolic markers.
TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Knee Osteoarthritis
Eli Lilly and Company
Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.
TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Knee Osteoarthritis
Eli Lilly and Company
Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.
TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Knee Osteoarthritis
Eli Lilly and Company
Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.
TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Knee Osteoarthritis
Eli Lilly and Company
Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.
Reported Side Effects
Phase 2 Trial of Retatrutide in Obesity, Type 2 Diabetes, and NASH
Jastreboff et al.
Retatrutide provided substantial weight reductions at 48 weeks with a tolerability profile similar to other incretin therapies; gastrointestinal side effects were most common during dose escalation.
TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Knee Osteoarthritis
Eli Lilly and Company
Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.
Phase 2 Trial of Retatrutide in Obesity, Type 2 Diabetes, and NASH
Jastreboff et al.
Retatrutide provided substantial weight reductions at 48 weeks with a tolerability profile similar to other incretin therapies; gastrointestinal side effects were most common during dose escalation.
TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Knee Osteoarthritis
Eli Lilly and Company
Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.
Phase 2 Trial of Retatrutide in Obesity, Type 2 Diabetes, and NASH
Jastreboff et al.
Retatrutide provided substantial weight reductions at 48 weeks with a tolerability profile similar to other incretin therapies; gastrointestinal side effects were most common during dose escalation.
TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Knee Osteoarthritis
Eli Lilly and Company
Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.
TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Knee Osteoarthritis
Eli Lilly and Company
Retatrutide achieved up to 28.7% weight loss at 68 weeks, improved pain and physical function, and reduced cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure.
Research (3 studies)
Community updates
No updates yet for this supplement.
Be the first to share your experience!
Stats
Notable users
· 3x/week (GLP-1 microdose)